Inclusion Criteria:

          -  Histologically confirmed and documented recurrent ovarian, fallopian tube, or
             peritoneal cancer. Only patients with high-grade serous adenocarcinoma histology are
             eligible.

          -  Aged 18 years or older

          -  Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1

          -  Platinum-resistant disease (defined as progression within ≤6 months from completion of
             most recent platinum-containing regimen and calculated from the date of the last
             administered dose of platinum therapy).

          -  Available archived tumor tissue or if archived tissue is not available, a fresh tumor
             biopsy.

          -  Received at least 1 but not more than 4 prior therapy regimens. Note: maintenance
             therapy OR hormonal therapies should not be counted as a separate therapy.

          -  Measurable disease according to RECIST v1.1 criteria

        Exclusion Criteria:

          -  Tumors in the breast or bone

          -  Untreated central nervous system (CNS) metastases (surgery and/or radiotherapy).
             Subjects requiring corticosteroid therapy for the management of their treated CNS
             metastases may not be on >10 mg/day prednisone or equivalent or have demonstrated
             signs or symptoms of neurologic instability for 28 days or less prior to
             randomization.

          -  Primary platinum-refractory disease (defined as progression during or within 4 weeks
             after completion of the first platinum regimen)

          -  Is being treated with concurrent anticancer therapy or other interventional treatments
             administered for their underlying ovarian cancer.

          -  Received prior therapy with PAC in the recurrent setting